Emerging Concepts for the Treatment of Hematological Malignancies with Therapeutic Monoclonal Antibodies
2010; Bentham Science Publishers; Volume: 11; Issue: 7 Linguagem: Inglês
10.2174/138945010791320845
ISSN1873-5592
AutoresAude-Hélène Capietto, Samarh Keirallah, Emilie Gross, Nicolas Dauguet, Emilie Laprévotte, Christine Jean, Julie Gertner-Dardenne, Christine Bezombes, Anne Quillet‐Mary, Mary Poupot, Loïc Ysebaert, Laurent Guy, Jean‐Jacques Fournié,
Tópico(s)Protein purification and stability
ResumoThe development of therapeutic monoclonal antibodies (mAbs) has revolutionized the treatment of cancer along the last ten years. The best examples of their therapeutic efficacies have been obtained with rituximab for the treatment of CD20+ B-cell Non-Hodgkin Lymphoma (B-NHL), and several others antibodies with optimized bioactivities are now being developed for the treatment of various malignant hemopathies. We review here the main drugs developed in this field, and present some emerging concepts able to improve the bioactivities of the next generation of therapeutic mAbs. Keywords: Cancer, lymphoma, therapy, antibodies, phosphoantigens
Referência(s)